Ad
related to: trastuzumab and pertuzumab combo list for 2 2020 download pdf 64-bit- Download Resources
For Healthcare Professionals
About A Treatment Option
- Request A Call Today
Get Updates, Resources & More
Information About TUKYSA®
- Safety Information
Access Clinical Safety Info
Keep Current On News For Physicians
- Prescribing Information
Download Prescribing Information
Additional Resources For Physicians
- Download Resources
Search results
Results from the WOW.Com Content Network
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
In 2013, trastuzumab emtansine was approved in the United States with the generic name "ado-trastuzumab emtansine", [18] [20] rather than the original United States Adopted Name (USAN) issued in 2009, "trastuzumab emtansine". [20] Trastuzumab is the anti-HER2 antibody; emtansine refers to the linker-drug (SMCC-DM1).
Trastuzumab has been shown to inhibit HER2/neu ectodomain cleavage in breast cancer cells. [64] Experiments in laboratory animals indicate that antibodies, including trastuzumab, when bound to a cell, induce immune cells to kill that cell, and that such antibody-dependent cell-mediated cytotoxicity is another important mechanism of action. [65]
[1] [2] It is a combination of trastuzumab and hyaluronidase. [ 1 ] [ 2 ] [ 3 ] The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction , upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity.
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [33] Twelve months of trastuzumab therapy is optimal.
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
Ad
related to: trastuzumab and pertuzumab combo list for 2 2020 download pdf 64-bit